Cabaletta Bio, Inc. Stock Price, News & Analysis

Cabaletta Bio, Inc. (CABA) reported its financial results for Q4 and FY 2020, highlighting significant milestones in its clinical trials. The company successfully dosed the first patient in a Phase 1 trial for DSG3-CAART, targeting mucosal pemphigus vulgaris, without dose limiting toxicities. Financially, R&D expenses increased to $21.4 million in 2020, up from $11.7 million in 2019. The company ended 2020 with $108.7 million in cash, down from $136.2 million a year earlier, ensuring funding through Q3 2022. Key milestones are anticipated in 2021, including additional trial data and an IND submission for MuSK-CAART.

Cabaletta Bio, Inc. (Nasdaq: CABA), a biotechnology firm specializing in engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in March 2021. The first is the Cowen & Co. 41st Annual Health Care Conference on March 3, where CEO Steven Nichtberger will engage in a cell therapy panel. The second is the H.C. Wainwright Global Life Sciences Conference on March 9, featuring a pre-recorded fireside chat. The discussion will be available on-demand post-conference on the company’s website for 90 days.

Cabaletta Bio, a clinical-stage biotechnology firm listed on Nasdaq as CABA, announced that its CEO, Steven Nichtberger, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 5:20 p.m. ET. A live webcast of the event will be available on the company's website and a recording will be accessible for 90 days post-event. Cabaletta is focused on engineered T cell therapies for B cell-mediated autoimmune diseases with its lead candidate, DSG3-CAART, currently in clinical trials.

Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), focuses on engineered T cell therapies for B cell-mediated autoimmune diseases. CEO Steven Nichtberger will present at two investor conferences on January 11, 2021. The presentations will be available via webcast on the company's website, starting at 6:00 a.m. and 7:00 a.m. ET respectively. The company's approach utilizes Chimeric AutoAntibody Receptor T cells, targeting specific autoantibody-producing B cells. Its leading candidate, DSG3-CAART, is in a phase 1 clinical trial for mucosal pemphigus vulgaris, with Fast Track Designation from the FDA.

Cabaletta Bio, Inc. (Nasdaq: CABA) achieved a significant milestone by infusing the first patient with its DSG3-CAART therapy during the DesCAARTes™ Phase 1 clinical trial. This trial aims to treat mucosal-dominant pemphigus vulgaris (mPV) and explores CAAR T cell technology for autoimmune diseases. DSG3-CAART could provide a more targeted and durable treatment option compared to current therapies that often induce broad immunosuppression. The trial will assess safety, tolerability, and early efficacy signs with an expected enrollment of 30 subjects across multiple sites in the U.S.

Cabaletta Bio, focused on engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in December 2020. Steven Nichtberger, M.D., the CEO, will partake in a pre-recorded chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 and a live discussion at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 3. The company’s pipeline includes DSG3-CAART, which targets mucosal pemphigus vulgaris and has received FDA Fast Track Designation. Webcast replays will be accessible for 90 days on their website.

Cabaletta Bio, Inc. (CABA) reported its Q3 2020 financial results, highlighting progress in its clinical programs. The company is actively enrolling patients in its Phase 1 trial for DSG3-CAART, aimed at treating mucosal pemphigus vulgaris, expecting to report acute safety data in the first half of 2021. Q3 R&D expenses rose to $5.7 million from $3.2 million in Q3 2019, and G&A expenses increased to $2.8 million from $1.8 million. As of September 30, 2020, cash and equivalents stood at $118.1 million, down from $136.2 million at year-end 2019, enough to fund operations through Q3 2022.

Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies for B cell-mediated autoimmune diseases, announced that CEO Steven Nichtberger will speak at three investor conferences in October 2020. The presentations include:

• Stifel 2020 Immunology and Inflammation Virtual Summit on October 1 at 3:00 p.m. ET.
• Jefferies Virtual Cell Therapy Summit on October 5 at 8:30 a.m. ET.
• Chardan 4th Annual Genetic Medicines Conference on October 6 at 11:30 a.m. ET.

Webcasts will be available on the company’s website.

Cabaletta Bio, a clinical-stage biotechnology company, announced that Dr. Steven Nichtberger will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 p.m. ET. A live webcast of the event will be available on their website, with a replay accessible for 90 days. The company is focused on engineered T cell therapies for B cell-mediated autoimmune diseases, leveraging their Cabaletta Approach to selectively eliminate specific B cells while preserving normal ones. Their lead candidate, DSG3-CAART, targets mucosal pemphigus vulgaris.